1. Antiviral effects of the fused tricyclic derivatives of indoline and imidazolidinone on ZIKV infection and RdRp activities of ZIKV and DENV.
- Author
-
Zhou, Guang-Feng, Li, Feng, Xue, Jian-Xia, Qian, Weiyi, Gu, Xue-Rong, Zheng, Chang-Bo, Li, Chunyan, Yang, Liu-Meng, Xiong, Si-Dong, Zhou, Guo-Chun, and Zheng, Yong-Tang
- Subjects
- *
ZIKA virus infections , *LIFE cycles (Biology) , *DRUG discovery , *ZIKA virus , *DENGUE viruses , *ANTIVIRAL agents , *INDOLINE , *QUINAZOLINONES , *HYDRAZINE derivatives - Abstract
• Fused tricyclic derivatives of indoline and imidazolidinone target ZIKV and its RdRp. • Some distinctive compounds are selective ZIKV inhibitors or DENV inhibitors. • Some broad-spectrum inhibitors of ZIKV- and DENV-infection are discovered. • 12, 17 and 28 are more active against Asian ZIKV strain than African ZIKV strain. • A compound's antiviral differentiation is not always related to anti-RdRp differentiation. • 12 majorly acts on post-infection of RNA synthesis stage of ZIKV life cycle. The prevalence and ravages of Zika virus (ZIKV) seriously endanger human health, especially causing significant neurological defects in both neonates as pediatric microcephaly and adults as Guillain–Barré syndrome. In this work, we studied anti-ZIKV effects of the fused tricyclic derivatives of indoline and imidazolidinone and discovered that some of them are valuable leads for drug discovery of anti-ZIKV agents. The current results show that certain compounds are broad-spectrum inhibitors of ZIKV- and dengue virus (DENV)-infection while distinctive compounds are selective ZIKV inhibitors or selective DENV inhibitors. Compounds of 12, 17 and 28 are more active against Asian ZIKV SZ-VIV01 strain than African ZIKV MR766 strain. It is valued that silylation makes six TBS compounds of 4-nitrophenyl hydrazine series and phenyl hydrazine series more active against ZIKV infection than their phenols. Time-of-addition and withdrawal studies indicate that compound 12 majorly acts on post-infection of RNA synthesis stage of ZIKV life cycle. Moreover, compounds of 12, 17 and 18 are anti-ZIKV agents with the inhibitory activities to ZIKV NS5 RdRp while 12 doesn't inhibit DENV infection even though it is a DENV RdRp inhibitor, 17 is an active agent against DENV infection but is only a weak DENV NS5 RdRp inhibitor, and 28 is inactive against DENV infection and not a DENV NS5 RdRp inhibitor. As a result, a compound's antiviral difference between ZIKV and DENV is not always related to anti-RdRp difference between ZIKV RdRp and DENV RdRp, and structural features of a compound play important roles in executing antiviral and anti-RdRp functions. Further discovery of highly potent broad-spectrum or selective agents against infection by ZIKV and DENV will be facilitated. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF